High throughput edge Carterra’s HT-SPR platforms deliver up to 100x throughput and 1% sample usage, enabling faster screening for therapeutic antibodies and small molecules. Target potential to upsell additional high-throughput screening packages and recurring maintenance for lab automation workflows.

AI driven design Origin-1 generative AI platform enhances antibody design with epitope-conditioned structures and co-folding scoring, presenting an opportunity to bundle AI-enabled design services with existing HT-SPR workflows to accelerate lead optimization.

Global reach Established Customer Experience Centers in multiple regions and exclusive distribution in APAC/Oceania through Revvity suggest expansion and services opportunities in regional labs, training partnerships, and localized support contracts.

Platform portfolio Recent launches include 48-channel HT-SPR and Ultra instruments, indicating a continuous upgrade cycle. Sales opportunities exist in upgrading existing customers, trade-ins, and cross-sell of newer modules to broaden screening capabilities.

Clinical discovery trend Focus on biotherapeutic discovery, developability and DEL hit derisking signals demand for integrated solutions combining binding assays, developability analytics, and label-free screening, enabling bundled offerings for end-to-end discovery programs.